Aeterna Zentaris Inc (NASDAQ:AEZS)

CAPS Rating: 5 out of 5

A growing global biopharmaceutical company focused on endrocrine therapy and oncology, in drug discovery, development and commercialization.

Recs

0
Player Avatar pchop123 (79.60) Submitted: 2/27/2013 11:58:29 AM : Underperform Start Price: $2.42 AEZS Score: -3.58

way overvalued

Featured Broker Partners


Advertisement